Cell Cure Raises $3 Million
Israeli startup Cell Cure Neurosciences has completed a $3 million funding round, $1 million of which was invested by Teva Pharmaceutical Industries.
Cell Cure’s controlling stakeholder, Singapore-based ES Cell International, will allow the company to continue stem cell research and not limit it to studying Parkinson’s disease, according to Israeli business daily Globes.
Cell Cure develops treatments based on embryonic stem cells for Parkinson’s and other neurodegenerative diseases. The firm hopes to begin human clinical trials in 2009.